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http://dx.doi.org/10.1016/j.stem.2015.10.008The Japanese government recently put in
placeasystemof standards, under theAct
on the Safety of Regenerative Medicine
(ASRM) (Konomi et al., 2015), for
reviewing and approving regenerative
medicine (RM) therapies. To obtain condi-
tional approval, the protocols must fulfill a
set of legal standards that varies in accor-
dance with the risk level of the cells to be
provided (see Figure S1). While this act
provides a new regulatory framework for
approving RM, providers of unapproved
RM therapies have not been legally pun-
ished under the new law as of yet.
On May 15, 2015, the Tokyo District
Court ruled in a case brought by a patient
against a private clinic at which the pa-
tient received treatment. The clinic (herein-
after X clinic) must reimburse the patient
approximately 1.34 million yen in therapy
costs and pay an additional half million
yen as damages for personal consolation
on thegroundsofabreachof theObligation
of Explanation (http://mainichi.jp/shimen/
news/20150516ddm041040025000c.html;
https://www.m3.com/news/iryoishin/325511).
The therapy provided by X clinic was an
allogeneic adipose-derivedmesenchymal
stem cell (ADMSC) infusion, which is
deemed Class I RM under ASRM (see
Supplemental Information).
To our knowledge, this is the first
instance in Japan of a patient bringing a
civil case against a private RM clinic for
damages. Although the US has seen a
number of similar lawsuits, these cases
have ended in pre-judgment settlements
(Drabiak-Syed, 2013; http://www.nytimes.
com/aponline/2015/05/18/us/ap-us-stem-
cells-clinics.html?_r=1; Hones v. Young,
2013). We are not aware of a similar civil
lawsuit and decision anywhere else in
the world, which underscores the unique-
ness of the case we report here.In general, adverse events can only be
resolved if regulations can be applied to
both (1) prevent violations (ex-ante regu-
lations) and (2) sanction or punish viola-
tions (ex-post regulations, including civil
action, criminal penalty, and administra-
tive sanction). ASRM prescribes penalties
for violators, but it is largely expected to
function primarily through its ex-ante pre-
ventative mechanisms. The court deci-
sion we describe here, however, may
have brought Japan one step closer to
realizing effective ex-post regulations for
private RM clinics.
Case Report and Analysis
Theplaintiff in this case is a 71-year-old fe-
male patient who suffered from chronic
kidney failure. She underwent a kidney
transplant in China in 2007. Meanwhile,
she had been experiencing unexplained
systemic numbness since her middle
age. In 2012—this case predated the
enactment of the ASRM—she met the
defendant, a plastic surgeon who worked
at X clinic. He told her that RM might
reduce her suffering and that he couldpro-
vide this service. She was initially con-
cerned about the safety of RM, but finally
decided to receive autologous ADMSC
infusion therapy at X clinic. The video
footage from the clinic, showing a wheel-
chair patient standing on his/her own
following a similar therapy, gave her hope
for cure. According to the plaintiff’s claim,
the nurse at X clinic told thepatient that her
health had improved after she received the
same RM—we have not discovered any
research proving that this was done as
part of a clinical study. The result of ablood
test revealed that the patient was a hepati-
tis B carrier. It is known that HBV may be
directly cytopathic in conditions of severe
immune suppression, and in such casesCell Stem Cell 17,the surgeon should have aborted cell
transplant. But, the surgeon offered and
performed allogeneic ADMSC infusion
therapy. According to the plaintiff’s claim,
the cultured stem cells were derived from
the adipose cells of a staff member work-
ing at an institution affiliated with X clinic.
Finally, for reasons unknown to us, the sur-
geon performed the therapy in the pa-
tient’s home, where he had limited access
to medical facilities, and thus could not
have performed emergency procedures
in response to any sudden changes in the
patient’s condition. Unfortunately, the pa-
tient’s numbness worsened after the ther-
apy; she can no longer walk, and is now
wheelchair-bound.
The Tokyo District Court held that the
surgeon did not have enough discussion
with the patient before finally recom-
mending X clinic’s stem cell therapy.
The surgeon proposed the allogeneic
ADMSC infusion therapy over the tele-
phone. Moreover, the surgeon failed to
offer the patient a description of the allo-
geneic ADMSC infusion therapy. The
patient signed the consent form for an
autologous procedure on the day of the
operation. The surgeon did not diagnose
the patient’s numbness, nor did he tell
her the risks associated with allogeneic
ADMSC infusion therapy for a kidney
transplant recipient. Although the patient
frequently asked about the risks, the sur-
geon repeatedly emphasized the lack
thereof. The defendants claimed that
they had fully explained the therapy to
the plaintiff and there was negligence on
the part of the plaintiff in not confirming
that she heard and understood the infor-
mation, but the judge did not recognize
this claim.
Although the sole point of dispute in the
lawsuit was the breach of the ObligationNovember 5, 2015 ª2015 Elsevier Inc. 507
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Letterof Explanation, the real issues in this case
were, in our understanding, the propriety
issues surrounding the medical care ac-
tions themselves, namely the issues
involving the risks inherent in the actions
performed by X clinic (the performance
of allogeneic ADMSC infusion therapy
for a patient who had undergone a kidney
transplant, despite the unverified safety
and efficacy of the therapy and the sur-
geon’s failure to diagnose the patient’s
numbness) and X clinic’s medical care
provision system (administering cells in
the patient’s home).
Implications: Overcoming the
Limits of Legal Regulations
Whether by ex-ante or ex-post regula-
tions, not all problems can be resolved
through legal regulations alone. Thus,
other stakeholders are forced to deal
with the limitations, taking into account
the actual situations within each private
clinic. First, we believe that the Japa-
nese Society for Regenerative Medicine
(JSRM) has a responsibility to continue
transmitting and disseminating more
effective information regarding inade-
quate clinics (http://www.asas.or.jp/jsrm/
announcements/110201.html, http://www.
asas.or.jp/jsrm/announcements/110303.
html). Second, the female patient in this
report hadbeenseeingaurologist regularly
prior to the case. Any competent primary
physician should advise his/her patient
against undergoing inadequate therapy
unsupported by medical evidence, and
medical efforts such as physician certifi-508 Cell Stem Cell 17, November 5, 2015 ª2cation programs are expected to provide
further support (http://www.asas.or.jp/
jsrm/members/certification_pdf/nintei/1_
kisoku2015.pdf). Third, a patient should
make the decision to undergo RM only
after gaining an adequate understanding
of the actual status of RM in Japan and of
the therapy he/she is seeking to undergo.
A number of incidents have occurred
around the world since the International
Society for Stem Cell Research issued
the ‘‘Guidelines for the Clinical Transla-
tion of Stem Cells’’ (http://www.isscr.org/
docs/guidelines/isscrglclinicaltrans.pdf) in
2008 (guidelines which are now under revi-
sion). Clearly, more needs to be done to
prevent such unfortunate incidents, and
we believe an important part of this is
sharing with other countries the cases
that emerge in our legal system.SUPPLEMENTAL INFORMATION
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